N-Methyl-2-aminoindane (NM-2-AI) is a synthetic stimulant of the aminoindane chemical class — the N-methyl derivative of 2-aminoindane (2-AI). By adding an N-methyl group to the primary amine of 2-AI, NM-2-AI occupies a structural position analogous to the methamphetamine/amphetamine relationship: an increase in lipophilicity and CNS penetrance expected to enhance potency and extend duration relative to the parent compound.
Like 2-AI, NM-2-AI is classified as a stimulant within the aminoindane family, believed to act primarily through dopamine and norepinephrine releasing activity with minimal serotonergic activity. The compound has been proposed to share 2-AI's purported non-neurotoxic profile (based on structural inference and limited animal data), but this claim is even less rigorously established for NM-2-AI than for 2-AI itself.
NM-2-AI remains one of the less-documented stimulant research chemicals. Community experience data are sparse, and the compound has attracted less attention than the more widely used fluorinated amphetamines or classic phenidates. The limited data available describe it as a mild-to-moderate stimulant with a generally clean, low-side-effect profile at typical doses — consistent with the aminoindane class character. However, the dose-response curve and upper limits of safe dosing are essentially uncharacterized.
Safety at a Glance
High Risk- Start Low and Go Slow
- The combination of minimal community data and expected higher potency than 2-AI (from N-methylation) makes starting v...
- Toxicity: Overview NM-2-AI's toxicity profile is essentially undocumented in formal literature. Like 2-AI, the primary risks ar...
- Dangerous with: 25x-NBOH, 25x-NBOMe, Atropa belladonna, Datura, MDMA (+3 more)
- Overdose risk: Stimulant overdose from NM-2-AI is a medical emergency primarily involving cardiovascular and neu...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 2 hrs – 4 hrsHow It Feels
NM-2-AI makes its presence known gradually and without fanfare. Within thirty to sixty minutes of oral ingestion, a gentle stimulation begins to emerge. It is a quiet compound, lacking the dramatic onset or pronounced euphoria of cathinone stimulants. Instead, there is a clean, steady increase in alertness and a mild elevation of mood that feels closer to the effect of a successful nap than to recreational drug use. The body warms slightly, and there is a subtle but real sense of increased energy and motivation.
At the peak, reached around one to two hours in, NM-2-AI provides a moderate, functional stimulation with a notably smooth character. The mind is clear and attentive. Focus is improved, though not to the degree offered by dedicated cognitive enhancers. The mood is gently positive, and there is an easygoing sociability that makes the compound suitable for social situations without making it particularly remarkable in that context. There is a physical warmth and lightness to the body that feels pleasant but unobtrusive. The overall experience occupies a middle ground between the functional austerity of phenidates and the emotional warmth of cathinones, without fully committing to either character.
Physical effects are mild. Heart rate may increase slightly, appetite is modestly suppressed, and there is a barely perceptible jaw tension. The aminoindane structure lends itself to a smoother, less physiologically aggressive profile than the cathinones, and users generally report feeling physically comfortable throughout. There is no significant vasoconstriction, no temperature dysregulation, and no pronounced sweating. The body functions normally within a slightly elevated range.
The effects last three to five hours and taper without incident. The comedown is among the gentlest of any stimulant: a gradual return of baseline fatigue and mood without any acute crash, emotional deficit, or rebound. Sleep is achievable within a reasonable timeframe. The following morning is unremarkable. The total impression of NM-2-AI is one of pleasant mediocrity, a compound that offers enough to justify its existence but not enough to generate enthusiasm. It is functional, tolerable, and forgettable in roughly equal measure.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(10)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Temporary erectile dysfunction— Temporary erectile dysfunction is the substance-induced inability to achieve or sustain a penile ere...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Cognitive & Perceptual Effects
Cognitive(13)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive fatigue— Mental exhaustion and difficulty sustaining thought after intense cognitive experiences, common duri...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Focus enhancement— An enhanced ability to direct and sustain attention on a single task or stimulus with unusual clarit...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Memory enhancement— Memory enhancement is a state of improved mnemonic function in which past memories become unusually ...
- Motivation enhancement— A heightened sense of drive, ambition, and willingness to accomplish tasks, making productive effort...
- Motivation suppression— Motivation suppression is a state of diminished drive and willingness to engage in goal-directed beh...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
Mechanism of Action
NM-2-AI is speculated to act primarily as a dopamine and norepinephrine releasing agent, based on its structural relationship to 2-AI and the broader amphetamine/aminoindane framework. The N-methyl group increases lipophilicity and generally enhances CNS penetrance, potentially increasing effective potency and extending duration relative to 2-AI.
Serotonergic activity is expected to be minimal — the aminoindane scaffold lacks the structural features (para-ring substituents, N-unsubstituted amine) associated with high SERT activity, and the N-methyl modification does not substantially alter this prediction. This distinguishes NM-2-AI from N-methylated MDMA analogs (like MDA) which have significant serotonergic activity.
Receptor Profile
- DAT — Presumed dopamine releasing activity; drives stimulation and wakefulness
- NET — Norepinephrine releasing activity; cardiovascular activation
- SERT — Minimal expected activity; non-entactogenic profile
Comparison to 2-AI
The N-methyl group is expected to increase potency (lower effective dose) and potentially extend duration compared to 2-AI. This means NM-2-AI doses should be correspondingly lower than 2-AI doses to achieve equivalent effects — a practical harm reduction consideration in the absence of precise dose data.
Pharmacokinetics
No formal human data available. Expected duration based on structural class: 3–6 hours orally.
Detection Methods
Standard Drug Panel Inclusion
NM-2-AI (N-Methyl-2-aminoindane) is a methylated aminoindane compound that is not detected on standard immunoassay drug screens. Like other aminoindanes, it lacks structural similarity to the amphetamine template targeted by commercial immunoassays. No extended panels specifically include NM-2-AI.
Urine Detection
NM-2-AI can be detected in urine for approximately 1 to 3 days following ingestion. Metabolism involves N-demethylation (producing 2-aminoindane), ring hydroxylation, and conjugation. Standard immunoassay screens will return negative results. Detection requires LC-MS/MS with NM-2-AI-specific reference standards.
Blood and Saliva Detection
Blood and oral fluid detection windows are estimated at 12 to 36 hours. The N-methyl group slightly alters the pharmacokinetic profile compared to the parent 2-aminoindane, but detection windows remain similar. Routine clinical and workplace testing panels do not target this compound.
Hair Follicle Detection
Hair follicle testing for NM-2-AI requires specialized forensic LC-MS/MS methods not available through standard commercial laboratories. Detection in hair is theoretically possible for up to 90 days.
Confirmatory Testing
LC-MS/MS and GC-MS can identify NM-2-AI and distinguish it from related aminoindanes. The N-methyl group produces distinct fragmentation patterns compared to 2-aminoindane. Chiral separation may be relevant if enantiomeric analysis is required.
Reagent Testing
Marquis reagent produces no significant reaction with NM-2-AI. Simon's reagent may produce a positive reaction (secondary amine), which can help distinguish it from primary amine aminoindanes. Mecke and Mandelin reagents show no characteristic reactions. Reagent testing alone is insufficient for identification.
Interactions
| Substance | Status | Note |
|---|---|---|
| 25x-NBOH | Dangerous | — |
| 25x-NBOMe | Dangerous | — |
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MDMA | Unsafe | — |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Dissociatives | Uncertain | — |
History
Origins in Aminoindane Chemistry
NM-2-AI was developed as a systematic N-methyl extension of the 2-aminoindane series. The aminoindane framework was explored in academic pharmaceutical research as a rigid analog of phenethylamines, and N-methylation was a natural structural modification in the exploration of the scaffold's pharmacological space.
Research Chemical Market
NM-2-AI entered the research chemical market alongside other aminoindane derivatives, part of the post-MDAI (5,6-methylenedioxy-2-aminoindane) exploration of non-serotonergic aminoindane stimulants. Its low market prominence reflects both the modest effect profile of the aminoindane stimulant class and the competition from more potent and well-characterized alternatives.
Regulatory Status
NM-2-AI is unscheduled in most jurisdictions. As a relatively obscure compound, it has not attracted specific regulatory attention; it remains accessible as a research chemical in many markets.
Harm Reduction
Start Low and Go Slow
The combination of minimal community data and expected higher potency than 2-AI (from N-methylation) makes starting very low essential:
- Suggested starting dose: 10–20 mg oral
- Wait the full expected duration (3–6 hours) before evaluating
- Increase only incrementally across multiple sessions
Do Not Combine with MAOIs
Absolute contraindication — hypertensive crisis risk.
Avoid Other Stimulants
Additive cardiovascular risk from combining stimulants.
Accept Data Limitations
NM-2-AI is a compound where the harm reduction principle "know before you go" is severely limited by the actual data available. The low community experience base means that serious rare adverse effects could exist and simply not be apparent yet.
Oral Route Only
Insufflation of aminoindane compounds is not recommended — there is no benefit justifying the mucosal irritation risk.
Toxicity & Safety
Overview
NM-2-AI's toxicity profile is essentially undocumented in formal literature. Like 2-AI, the primary risks are cardiovascular and psychological, consistent with a dopaminergic/noradrenergic stimulant. The N-methyl modification likely increases potency and potentially the cardiovascular activation per dose relative to 2-AI.
Neurotoxicity Assessment
Based on structural class and proposed mechanism (primarily dopaminergic/noradrenergic, minimal serotonergic activity), NM-2-AI likely lacks the specific serotonergic neurotoxicity associated with para-substituted amphetamines. However, structural inference is not equivalent to safety data. Chronic high-dose use of any dopaminergic releasing agent can produce dopaminergic neurotoxicity.
Cardiovascular Risk
Standard sympathomimetic cardiovascular risks — tachycardia, elevated blood pressure — apply. Potency increase from N-methylation means these effects may be more pronounced per milligram than with 2-AI.
Data Gap Warning
NM-2-AI represents a compound where the risk is genuinely unknown rather than "probably comparable to X." The sparse community experience means dose thresholds for toxicity, maximum safe doses, and interaction risks are undocumented.
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Stimulant overdose from NM-2-AI is a medical emergency primarily involving cardiovascular and neurological toxicity.
Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.
Emergency response:
- Call emergency services immediately
- Keep the person cool (remove excess clothing, apply cool water)
- If seizures occur, protect the head and clear the area of hard objects
- If the person loses consciousness, place in recovery position
- Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionals
Prevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
NM-2-AI is currently believed to be a grey area compound within most parts of the world. This means that it is not known to be specifically illegal within any country but people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.
Germany: NM-2-AI is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Switzerland: NM-2-AI is a controlled substance specifically named under Verzeichnis E.
United Kingdom: It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
Responsible use
2-AI
Stimulants
NM-2-AI (Wikipedia)
NM-2-AI (Isomer Design)
Tips (5)
Avoid binge patterns with NM-2-AI. Sleep deprivation combined with stimulant use dramatically increases psychosis risk after 48+ hours awake. If you find yourself redosing to avoid the comedown, that is a major warning sign.
Do not take NM-2-AI in the afternoon or evening if you want to sleep that night. Most stimulants have long half-lives and even if you feel you can sleep, the quality will be significantly impaired.
Weigh your dose of NM-2-AI with a milligram scale. Street stimulants vary wildly in purity and potency. What looks like a normal amount could be significantly stronger than expected, especially with a new batch.
Start low with NM-2-AI and wait for full onset before redosing. Stimulant redosing extends duration and side effects more than it extends euphoria, while adding cardiovascular strain. Set a firm limit before you start.
Eat a substantial meal before taking NM-2-AI. Stimulants suppress appetite heavily, and going many hours without food leads to worse crashes, irritability, and cognitive impairment. Set phone reminders to eat and drink.
See Also
References (4)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- PubChem: NM-2-AI
PubChem compound page for NM-2-AI (CID: 15023225)
pubchem - NM-2-AI - TripSit Factsheet
TripSit factsheet for NM-2-AI
tripsit - NM-2-AI - Wikipedia
Wikipedia article on NM-2-AI
wikipedia